Appendix Table C3. Survival and local control outcomes of studies that address Key Question 1

| Study | Survival Outcomes for Intervention Group 1 | Survival Outcomes for Intervention Group 2 | Local Control Outcomes for Intervention Group 1 | Local Control Outcomes for Intervention Group 2 | Arm |
| --- | --- | --- | --- | --- | --- |
| Andratschke 2011, #132 | SBRT:**Overall survival:** Median 29 months1-year: 79%3-years: 38%5-years: 17%**Cancer/disease specific** **survival:**Median 46 months1-year: 93% 3-years: 64% 5-years: 48% | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**1-year: 89%3-years: 83% 5-years: 83%  | **Local control:**NA | No |
| Baumann2006, #271 | SBRT**Overall survival:** 3-year: 52%5-year: 26%**Cancer/disease specific** **survival:**3-year: 66%5-year: 40% | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**88%Time to failure: 17.8 (10-49)months | **Local control:**NA | No |
| Baumann2009, #270  | SBRT**Overall survival:** Median: 40.6 months1-year: 68%2-years:65%3-years:60%**Cancer/disease specific** **survival:**1-year: 93%2-years:88%3-years:88% | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**3-years: 92% | **Local control:**NA | No |
| Bogart-2010, #382 | 3DRT**Overall survival:** Median: 38.5 months (95% CI: 22.4 to 58.7)**Cancer/disease specific** **survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | 3DRT**Local control:**93% | **Local control:**NA | No |
| Bollineni-2012,#4548 | SBRT:**Overall survival:** Median NR2-years high SUV: 62%2-years low SUV: 81%**Cancer/disease specific** **survival:**Median NR2-years high SUV: 74%2-years low SUV: 90% | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**2-years: 96%  | **Local control:**NA | No |
| Bradley-2003, #445 | 3DRT**Overall survival:** 1-year: 73%2-year: 51%3-year: 34%**Cancer/disease specific** **survival:**1-year: 82%2-year: 67%3-year: 51% | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | 3DRT**Local control:**1-year: 88%2-year: 69%3-year: 63% | **Local control:**NA | No |
| Burdick-2010, #521 | SBRT**Overall survival:** 2-year: 33% (95% CI: 18%-51%)**Cancer/disease specific** **survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**2-year: 94% | **Local control:**NA | No |
| Bush-2004, #535 | PBRT**Overall survival:** Total 3-year: 44%Rx 51 CGE, 3-year: 27%Rx: 60 CGE, 3-year: 55%(p=0.03)**Cancer/disease specific****survival:**3-year: 72% | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | PBRT**Local control:**3-year:74% | **Local control:**NA | No |
| Campeau 2009, #565 | 3DRT**Overall survival:** 2-year: 61.3%**Cancer/disease specific survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | 3DRT**Local control:**2-year: 85% | **Local control:**NA | No |
| Coon-2008, #803 | SBRT**Overall survival:** 11 months: 81% **Cancer/disease specific****survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**11 months: 85% | **Local control:**NA | No |
| Dunlap-2010, #1032 | SBRT**Overall survival:**Median: 20.1 months (95% CI: 18.7-28.4) 1-year: 85%2-year:45%**Cancer/disease specific****survival:**3-year: 82% | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**2-year: 83%Stage IA, 2-years:90%Stage IB, 2-years: 70%(p=0.035) | **Local control:**NA | No |
| Fritz-2008, #1238 | SBRT**Overall survival:**Median:37 months2-year: 66%3-year:53%**Cancer/disease specific****survival:**2-year:71%3-year:57% | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**3-year: 81% | **Local control:**NA | No |
| Graham-2006, #1403 | 3DRT**Overall survival:** Median 43 months5-years: 30% (95% CI: 13-48%) **Cancer/disease specific** **survival:**5-years: 53% (95% CI: 28-72%)  | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | 3DRT**Local control:**NA | **Local control:**NA | No |
| Iwata-2010, # 1747  | **Overall survival:** 3-years: 65% **Cancer/disease specific survival:** NR | **Overall survival:**NA**Cancer/disease specific survival:** NA | **Local control:**NR | **Local control:**NA | Yes |
| Jimenez-2010, #1842 | 3DRT**Overall survival:** 3-years: 44% (95% CI: 28-58%)**Cancer/disease specific****survival:**NR | **Overall survival:**NA**Cancer/disease specific****survival:**NA | 3DRT**Local control:**NR | **Local control:**NA | No |
| Kopek-2009, #2040 | SBRT**Overall survival:** Median 22 months1-year: 67%2-years: 49%3-years: 36%4-years: 24%5-years: 21%**Cancer/disease specific** **survival:**Median 61 months | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**4-years: 89% | **Local control:**NA | No |
| Mirri-2009, #2576 | 3DRT**Overall survival:** 1-year: 81%3-years: 61%**Cancer/disease specific** **survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | 3DRT**Local control:**1-year: 88%3-years: 72% | **Local control:**NA | No |
| Nakayama2010, #2684 | PBRT**Overall survival:** 2-years: 98% (95% CI, 94-102%)**Cancer/disease specific** **survival:**2-years: 100% | **Overall survival:**NA**Cancer/disease specific survival:** NA | PBRT**Local control:**2-years: 97% (95% CI, 91-103%) | **Local control:**NA | No |
| Narayan-2004, #2686 | 3DRT**Overall survival:** 2-years: 54%3-years: 33%**Cancer/disease specific** **survival:**2-years: 76%3-years: 48% | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | 3DRT**Local control:**77% | **Local control:**NA | No |
| Nyman-2006,#2750 | SBRT**Overall survival:**Median: 39 months1-year: 80%2-years: 71%3-years: 55%5-years: 30% **Cancer/disease specific** **survival:**Median: 55 months1-year: 88%2-years: 83%3-years: 67%5-years: 41% | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**80%  | **Local control:**NA | No |
| Olsen-2011, #2792 | SBRT**Overall survival:** Median overall : 14 months (not reached)Median 34 months for each dose group**Cancer/disease specific** **survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**45 Gy: 1-year: 75% 2-years: 50%50 Gy:1-year: 100%2-years: 100%54 Gy:1-year: 99%2-years: 91% | **Local control:**NA | No |
| Palma 2012, #2843 | SBRT**Overall survival:** Median: 32 months1-year: 79%3-years: 47%5-years: 28%**Cancer/disease specific** **survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**3-years: 89% | **Local control:**NA | No |
| Pennathur 2007, #2896 | RFA**Overall survival:** Median not reachedProbability at 1-year: 95% (95% CI, 85-100%)Probability at 2-years: 68% (95% CI, 49-96%)**Cancer/disease specific** **survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | RFA**Local control:**58%  | **Local control:**NA |  |
| Pennathur 2009, #2898 | SBRT**Overall survival:** Median 26.4 (68% CI, 19.6-not reached) months1-year: 81% (68% CI, 73-90%)**Cancer/disease specific** **survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**58%  | **Local control:**NA | No |
| Ricardi-2010, #3098 | SBRT**Overall survival:** Median not reached 2-years: 69%3-years: 57% **Cancer/disease specific** **survival:**2-years: 79%3-years: 72% | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**3-years: 88% | **Local control:**NA | No |
| Scorsetti-2007, Italy, #3362 | SBRT**Overall survival:** 1-year: 93±5%2-years: 53±11%**Cancer/disease specific** **survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**NR | **Local control:**NA | No |
| Shibamoto 2012, #4629 | SBRT:**Overall survival:** Median ~52 months3-years: 59%5-years: 44%**Cancer/disease specific** **survival:**NR by operability | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**NR by operabilty | **Local control:**NA | No |
| Song-2009, #3549 | SBRT**Overall survival:** 1-year: 71%2-years: 38%**Cancer/disease specific** **survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**1-year: 85%2-years: 85% | **Local control:**NA | No |
| Stephans 2009, #3614 | SBRT**Overall survival:** 1-year: 81% (all patients)1.5-years: 75% (all patients)1-year: 83% (50 Gy)1-year: 77% (60 Gy)**Cancer/disease specific** **survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**6-months:100% (all patients)1-year: 98% (all patients)1.5-years: 95% (all patients)1-year: 97% (50 Gy)1-year: 100% (60 Gy) | **Local control:**NA | No |
| Taremi-2011, Canada, #3732 | SBRT**Overall survival:** All patients1-year: 84% (95% CI, 76-90%)4-years: 30% (95% CI, 15-46%)**Cancer/disease specific** **survival:**All patients1-year: 92% (95% CI, 87-98%)4-years: 77% (95% CI, 64-89%) | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**All patients1-year: 92% (95% CI, 86-97%)4-years: 89% (95% CI, 81-96%)Biopsy-proven1-year: 93% (95% CI, 87-98%)Nonbiopsy-proven1-year: 87% (95% CI, 76-99%)p = 0.41 versus biopsy-proven | **Local control:**NA | No |
| Takeda-2009, #3700 | SBRT**Overall survival:** 3-years: 90% (stage IA)3-years: 63% (stage IB) p = 0.093-years: 77% (inoperable) p = 0.31**Cancer/disease specific survival:**3-years: 100% (stage IA)3-years: 81% (stage IB) p = 0.103-years: 94% (inoperable) p = 0.66 | **Overall survival:**NA**Cancer/disease specific survival:** NA | SBRT**Local control:**3-years: 93% (stage IA)3-years: 96% (stage IB) p = 0.86 | **Local control:**NA | No |
| Turzer-2011, #3842 | SBRT**Overall survival:** 97% (calculated)**Cancer/disease specific** **survival:**NR | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**1.5 years: 100% | **Local control:**NA | No |
| Vahdat-2010, #3864 | SBRT**Overall survival:** 2-years: 90%**Cancer/disease specific** **survival:**85% (calculated) | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**2-years: 95% | **Local control:**NA | No |
| van der Voort van Zyp-2009, #3885 | SBRT**Overall survival:** 1-year: 83% (95% CI, 71-90%)2-years: 62% (95% CI, 45-75%)**Cancer/disease specific** **survival:**1-year: 94%2-years: 86% | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**60 Gy2-years: 78% (95% CI, 84-99%)45 Gy2-years: 78% (95% CI, 37-94%) | **Local control:**NA | No |
| Videtic-2010, #3958 | SBRT**Overall survival:** Median 38 months3-years: 52%**Cancer/disease specific** **survival:**SBRT69% (calculated) | **Overall survival:**NA**Cancer/disease specific** **survival:** NA | SBRT**Local control:**3-years: 94% | **Local control:**NA | No |